奥利司他对肥胖伴非酒精性脂肪性肝病的作用及危险因素的影响

To evaluate the efficacy of orlistat in the treatment of obesity with non-alcoholic fatty liver disease.Orlistat 120mg, three times per day for a couse of 24 weeks, were given to the 30 cases non-alcoholic fatty liver disease (NAFLD) patients whose body mass index (BMI) were between 25 and 32.After 24 weeks treatment, mean weight、BMI、waist and waist/hip ratio (WHR) and blood pressure was significantly decreased (P<0.001) ;Liver functions (ALT、AST、GGT、TG and Tch) and IR was significantly decreased (P<0.001) ;The liver density value by CT scan and liver/spleen ratio by CT scan was significantly increased (P<0.001) .Orlistat can decrease the fat deposit on liver of NAFLD, improve the liver function and metabolic syndrome.It is a drug choice for obese patients with NAFLD.